International Psoriasis Council
Advancing Knowledge. Improving Care.
Learn how psoriasis severity is defined and what NPF’s endorsement of IPC’s framework means for classifying mild versus moderate to
The 2025 IPC Think Tank Congress Report highlights psoriasis as a systemic immunometabolic disease, linking obesity, cardiovascular risk, biomarkers, and
A new IPC consensus in the Journal of the American Academy of Dermatology provides clear, expert-backed guidance on defining failure
Artificial intelligence is transforming psoriasis care by improving diagnosis accuracy, guiding treatment decisions, and supporting personalized management.
<div class="addtoany_share_save_container addtoany_content
At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and treatment. Highlights include
IPC Councilor Dr. Tiago Torres provides expert commentary on research linking psoriasis severity to cardiovascular disease via systemic inflammation. The
The updated IPC psoriasis severity classification gains broader clinical and global acceptance, emphasizing impact over body surface area, and growing
Discover the new free psoriasis course on WHOAcademy, created by IPC and IFPA for the WHO. Enhance your knowledge of
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes
The Psoriasis: From Gene to Clinic Congress Report highlights breakthroughs in genetics, clinical care, and treatment advancements for psoriasis, featuring
The 2024 IPC Think Tank Congress Report provides a comprehensive summary of key topics, including the epidemiology of psoriasis, genetic
The 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC Symposium on Data-Driven
This report from the 53rd Annual ESDR Meeting in Lisbon covers key presentations on psoriasis, including updates from the IPC
Uncover the true impact of psoriasis and learn about critical steps to improve diagnosis, treatment, and patient support in the
Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving understanding of psoriasis management,
Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This
The IPC is proud to announce a collaboration with the National Psoriasis Foundation (NPF) in unveiling new insights into the
In this enlightening blog post, Dr. Andrew Alexis, an esteemed Professor of Clinical Dermatology, delves into the intricacies of diagnosing
Discover the latest insights on psoriasis treatment for individuals with skin of color in our comprehensive blog post. Learn about
This blog post provides a comprehensive overview of psoriasis in individuals with skin of color. It explores the prevalence of
El Proyecto de Reclasificación de la Severidad de la Psoriasis de los Consejos Internacionales de Psoriasis tiene como objetivo cambiar
O Projeto de Reclassificação da Gravidade da Psoríase do Conselho Internacional de Psoríase visa alterar a classificação da gravidade da
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion
The IPC Disease Severity Working Group concluded that the objective measures of two commonly used clinical tools to determine psoriasis
In moderate to severe psoriasis, there has been a long-lasting tradition to define outcome as a relative change from baseline
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.